羊膜市場 - 副產品（冷凍保存、冷凍乾燥）、應用（手術傷口、眼科、幹細胞生物學、再生醫學、產前診斷）、最終用途（醫院、專科診所） - 全球預測，2024 年 - 2032 年

由於組織工程和再生醫學技術的進步，以及羊膜產品的日益普及，全球羊膜市場從 2024 年到 2032 年的複合年成長率將達到 11.2%。這些創新為各個醫學專業的傷口癒合和組織修復提供了有前景的解決方案。隨著在眼科、骨科和傷口護理領域的廣泛應用，羊膜因其再生特性而越來越受到青睞。隨著人們認知的提高和醫療保健專業人員親眼目睹其好處，對這些先進療法的需求將推動羊膜產業的成長。

例如，2022 年 11 月，Versaa 推出了 Biovance 3L 眼部三層人羊膜，為眼科應用提供先進的再生能力。

羊膜市場根據產品、應用、最終用途和地區進行分類。

由於眼部疾病盛行率上升以及眼科手術擴大採用羊膜產品，到 2032 年，眼科領域將獲得可觀的效益。隨著眼部護理技術的進步，這些膜可以有效治療角膜潰瘍和結膜炎等疾病。眼科醫生青睞這些產品，因為它們具有再生特性和促進癒合的能力。隨著對創新眼部護理解決方案的需求上升，眼科領域將保持其在羊膜行業的主導地位。

由於致力於先進傷口護理和再生醫學的專業診所數量不斷增加，到 2032 年，專業診所領域的羊膜產業規模將獲得可觀的估值。這些診所提供使用羊膜產品治療各種病症的針對性方法。隨著患者對微創手術的偏好激增以及這些膜在傷口癒合中的有效性，專科診所處於最前線。他們對提供專業護理的承諾將大大有助於他們在市場上的主導地位。

受手術數量增加、人們對羊膜產品益處的認知不斷提高以及醫療基礎設施不斷發展等因素的推動，亞太地區羊膜行業在 2024 年至 2032 年間將以顯著的複合年成長率成長。中國和印度等國家是這一成長的主要貢獻者，它們擁有龐大的患者群體和不斷擴大的醫療設施。此外，該地區對研發的關注將進一步鞏固亞太地區作為羊膜市場關鍵貢獻者的地位。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 再生醫學需求不斷成長
    • 慢性傷口的發生率上升
    • 生物技術與組織工程的進步
    • 提高羊膜產品的認知度與接受度
  • 產業陷阱與挑戰
    • 羊膜產品保存期限有限
    • 嚴格的監理政策
• 成長潛力分析
• 技術景觀
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

• 主要趨勢
• 冷凍保存
• 凍乾的

第 6 章：市場估計與預測：按應用分類，2018 年 - 2032 年

• 主要趨勢
• 手術傷口
• 眼科
• 幹細胞生物學
• 再生醫學
• 產前診斷
• 其他應用

第 7 章：市場估計與預測：按最終用途，2018 - 2032 年

• 主要趨勢
• 醫院
• 門診手術中心 (ASC)
• 專科診所
• 研究和學術機構
• 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Alliqua BioMedical Inc.
• Alynx, Co.
• Amnio Technology, LLC
• Applied Biologics LLC
• BioTissue Holdings Inc.
• Corza Health, Inc.
• Integra LifeSciences Corporation
• Organogensis, Inc.
• Skye Biologics, Inc.
• TissueTech, Inc.

Global Amniotic Membrane Market will register 11.2% CAGR from 2024 to 2032, attributed to advancements in tissue engineering and regenerative medicine technologies, coupled with the growing adoption of amniotic membrane products. These innovations offer promising solutions for wound healing and tissue repair across various medical specialties. With versatile applications in ophthalmology, orthopedics, and wound care, amniotic membranes are increasingly favored for their regenerative properties. As awareness grows and healthcare professionals witness the benefits firsthand, the demand for these advanced therapies will fuel the growth of the amniotic membrane industry.

For instance, in November 2022, Versea introduced the Biovance 3L ocular tri-layer human amniotic membrane, offering advanced regenerative capabilities for ophthalmic applications.

The amniotic membrane market is classified based on product, application, end-use, and region.

The ophthalmology segment will amass considerable gains by 2032, propelled by the rising prevalence of ocular disorders and the increasing adoption of amniotic membrane products for ophthalmic surgeries. With advancements in eye care technology, these membranes offer effective treatment for conditions like corneal ulcers and conjunctivitis. Ophthalmologists favor these products for their regenerative properties and ability to promote healing. As demand for innovative eye care solutions rises, the ophthalmology segment will maintain its dominance in the amniotic membrane industry.

The amniotic membrane industry size from the specialty clinics segment will secure a substantial valuation by 2032 due to the increasing number of specialized clinics dedicated to advanced wound care and regenerative medicine. These clinics offer a focused approach to treating various conditions using amniotic membrane products. With a surge in patient preference for minimally invasive procedures and the effectiveness of these membranes in wound healing, specialty clinics are at the forefront. Their commitment to providing specialized care will contribute significantly to their dominance in the market.

Asia Pacific amniotic membrane industry will grow at a notable CAGR between 2024 and 2032, fueled by factors such as the rising number of surgeries, increasing awareness about the benefits of amniotic membrane products, and the growing healthcare infrastructure. Countries like China and India are key contributors to this growth, with their large patient populations and expanding healthcare facilities. Additionally, the region's focus on research and development will further solidify Asia Pacific's position as the pivotal contributor to the amniotic membrane market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing demand for regenerative medicine
    • 3.2.1.2 Rising incidence of chronic wounds
    • 3.2.1.3 Advancements in biotechnology and tissue engineering
    • 3.2.1.4 Increasing awareness and acceptance of amniotic membrane products
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited shelf life of amniotic membrane products
    • 3.2.2.2 Stringent regulatory polices
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cryopreserved
• 5.3 Lyophilized

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Surgical wounds
• 6.3 Ophthalmology
• 6.4 Stem cell biology
• 6.5 Regenerative medicine
• 6.6 Prenatal diagnosis
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers (ASCs)
• 7.4 Specialty clinics
• 7.5 Research and academic institutes
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Alliqua BioMedical Inc.
• 9.2 Alynx, Co.
• 9.3 Amnio Technology, LLC
• 9.4 Applied Biologics LLC
• 9.5 BioTissue Holdings Inc.
• 9.6 Corza Health, Inc.
• 9.7 Integra LifeSciences Corporation
• 9.8 Organogensis, Inc.
• 9.9 Skye Biologics, Inc.
• 9.10 TissueTech, Inc.